Evidence map›Paper›PMID 40425457›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025

[Screening of MLL fusion genes and rare breakpoint cases in patients with acute myeloid leukemia].

S Li, H C Cheng, Z Y Wang, W P Hao, H Liang, J Ma

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

S LiHematology and Tumor Research Center of Harbin First Hospital, Harbin 150010, China.
H C ChengHematology and Tumor Research Center of Harbin First Hospital, Harbin 150010, China.
Z Y WangHematology and Tumor Research Center of Harbin First Hospital, Harbin 150010, China.
W P HaoHematology and Tumor Research Center of Harbin First Hospital, Harbin 150010, China.
H LiangHematology and Tumor Research Center of Harbin First Hospital, Harbin 150010, China.
J MaHematology and Tumor Research Center of Harbin First Hospital, Harbin 150010, China.

Funding

Science and Technology Plan Project of Heilongjiang Provincial Bureau of Traditional Chinese Medicine ZHY2022-006Science and Technology Plan Project of Heilongjiang Provincial Health Commission 20220303040950
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionAdultAgedAged, 80 and overChromosome BreakpointsFemaleHumansIn Situ Hybridization, FluorescenceKaryotypingMaleMiddle AgedPrognosisTranslocation, GeneticYoung AdultMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionFluorescence in situ hybridizationGene, MLLKaryotype analysisLeukemia, myeloid, acute

Identifiers

PMID40425457
PMCPMC12158805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.